Loading...
XNAS
PALI
Market cap355mUSD
Jul 09, Last price  
1.97USD
1D
-3.90%
1Q
8.24%
Jan 2017
-100.00%
IPO
-100.00%
Name

Palisade Bio Inc

Chart & Performance

D1W1MN
XNAS:PALI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
197.87%
Rev. gr., 5y
-0.78%
Revenues
0k
265,759306,05700733,438390,625407,708110,00018,83310,41716,246260,000260,00015,394000250,00000
Net income
-17m
L+16.23%
-3,147,000-7,063,000-11,830,798-10,364,363-18,387,000-12,519,000-10,122,000-19,832,000-22,629,000-20,904,000-21,075,000-15,666,000-4,925,000-8,352,000-10,322,000-26,616,000-14,260,000-12,300,000-14,438,000-16,781,000
CFO
-11m
L-11.04%
-3,334,927-4,001,368-6,860,039-5,144,820-9,981,244-8,096,696-8,477,700-10,591,617-11,706,688-18,931,666-15,616,108-13,416,162-7,692,419-7,255,680-4,768,000-14,773,000-13,360,000-11,133,000-12,193,000-10,847,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
URL
https://palisadebio.com/
IPO date
Dec 20, 2006
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT